This 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects (1:1:1) to once-daily
liraglutide (1.2 or 1.8 mg) or
liraglutide placebo in combination with
metformin (1 g twice daily) and
rosiglitazone (4 mg twice daily). Subjects had
type 2 diabetes, A1C 7-11% (previous oral antidiabetes
drug [OAD] monotherapy >or=3 months) or 7-10% (previous OAD combination
therapy >or=3 months), and BMI <or=45 kg/m(2).
RESULTS: Mean A1C values decreased significantly more in the
liraglutide groups versus placebo (mean +/- SE -1.5 +/- 0.1% for both 1.2 and 1.8 mg
liraglutide and -0.5 +/- 0.1% for placebo). Fasting plasma
glucose decreased by 40, 44, and 8 mg/dl for 1.2 and 1.8 mg and placebo, respectively, and 90-min postprandial
glucose decreased by 47, 49, and 14 mg/dl, respectively (P < 0.001 for all
liraglutide groups vs. placebo). Dose-dependent
weight loss occurred with 1.2 and 1.8 mg
liraglutide (1.0 +/- 0.3 and 2.0 +/- 0.3 kg, respectively) (P < 0.0001) compared with
weight gain with placebo (0.6 +/- 0.3 kg). Systolic blood pressure decreased by 6.7, 5.6, and 1.1 mmHg with 1.2 and 1.8 mg
liraglutide and placebo, respectively. Significant increases in
C-peptide and homeostasis model assessment of beta-cell function and significant decreases in the
proinsulin-to-
insulin ratio occurred with
liraglutide versus placebo. Minor
hypoglycemia occurred more frequently with
liraglutide, but there was no major
hypoglycemia. Gastrointestinal adverse events were more common with
liraglutide, but most occurred early and were transient.
CONCLUSIONS: